Compare MobilEye Global Inc (MBLY) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MobilEye Global Inc vs Revvity Inc — how do they compare? MobilEye Global Inc trades at $7.12 (market cap $6.00B), while Revvity Inc trades at $154.1 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 2.8× MobilEye Global Inc's market cap, and Revvity Inc pays a 0.18% dividend while MobilEye Global Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold MobilEye Global Inc for 15 Days and Revvity Inc for 12 Days on average.
| MBLY | RVTY | |
|---|---|---|
Market Cap | $6.00B | $16.98B |
Volume | 7,007,849 | 1,456,900 |
Sector | Consumer Cyclical | Health |
52-Week High | $15.42 | $157.36 |
52-Week Low | $6.56 | $82.26 |
Typical Hold Time | 15 Days | 12 Days |
Enterprise Value | $4.56B | $19.30B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mobileye Global (MBLY) trades at $7.11, down 0.56% on the day, with a bearish technical outlook but mixed fundamental signals. The stock shows negative profitability with a net income margin of -201.49% for 2026, yet revenue grew to $2.0 billion. Recent earnings beats in Q1 and Q2 2026 contrast with a Q4 2025 miss, while analyst consensus is a 'Buy' with a $10.83 price target. News highlights ADAS momentum and a robotaxi strategy expansion, but the stock faces significant cash flow volatility.
The outlook for MBLY is cautious; while analyst optimism and revenue growth provide upside potential, persistent losses and bearish technicals pose risks. Investment opportunity hinges on execution of autonomous driving programs, but shareholders face volatility from negative earnings and high valuation multiples like EV/EBITDA of 32.34.
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
